Business
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical
About this update from Estrella Immunopharma, Inc.
[{"type":"text","content":" EMERYVILLE, Calif.--(BUSINESS WIRE)--\nEstrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company’s differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103.\n\n\n“The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to place on differentiated cell therapy engineering platforms,” said Dr. Cheng Liu, President and Chief Executive Officer of Estrella. “Estrella believes that its ARTEMIS platform, and the early clinical signals observed in STARLIGHT-1, position the Company as a meaningful participant in the next wave of CAR-T innovation.”\n\n\nKey Insights from Zacks SCR’s Initiation Report:\n\n\n\nPromising Early Efficacy in High-Risk Patients: Zacks SCR highlights Phase I data from the STARLIGHT-1 trial presented at the 2026 ASTCT & CIBMTR Tandem Meetings. Among the 9 patients in Phase I, no treatment-related serious adverse events were reported, and the high-dose cohort achieved a 100% complete response rate at Month 1 in all 5 evaluable patients. The enrolled patient population (n=9) was heavily pretreated, with a median of three prior lines of therapy. Approximately 80% of the enrolled patients were considered high-risk, including patients with primary refractory disease, high-grade B-cell lymphoma, and primary CNS lymphoma. All subjects who achieved a CR remained in CR at the time of data cutoff, with a median duration of complete response not yet reached and CR durations ranging from 3 to 18 months.\n\n\n\n\nFavorable Safety Profile: EB103 demonstrated a potentially more favorable safety profile relative to existing CAR-T therapies in the nine patients treated in Phase I to date. While Cytokine Release Syndrome (CRS) was observed in all treated patients, all CRS events were low grade (Grade 1 or 2) and managed with standard of care. There were no instances of Grade 3 or higher CRS observed at eithe...